Erratum Regarding “Managing Hyperkalemia to Enable Guideline-Recommended Dosing of Renin-Angiotensin-Aldosterone System Inhibitors” *(Am J Kidney Dis. 2022;80[2]:159-160)*

In the Editorial entitled “Managing Hyperkalemia to Enable Guideline-Recommended Dosing of Renin-Angiotensin-Aldosterone System Inhibitors” that appeared in the August 2022 issue of *AJKD* (Palmer and Clegg, volume 80, issue 2, pages 159-160), there was an error in the financial disclosure statement. The corrected statement is “Financial Disclosure: Dr Palmer reports receipt of consultancy and speaker fees from Relypsa and AstraZeneca. Dr Clegg is the spouse of Dr Palmer.”


In the Core Curriculum entitled “Physiology and Pathophysiology of Potassium Homeostasis: Core Curriculum 2019” that appeared in the November 2019 issue of *AJKD* (Palmer and Clegg, volume 74, issue 5, pages 682-695), there was an error in the financial disclosure statement. The corrected statement is “Financial Disclosure: Dr Palmer reports receipt of consultancy and speaker fees from Relypsa and AstraZeneca. Dr Clegg is the spouse of Dr Palmer.”

Erratum Regarding “Potassium Homeostasis in Health and Disease: A Scientific Workshop Cosponsored by the National Kidney Foundation and the American Society of Hypertension” *(Am J Kidney Dis. 2017;70[6]:844-858)*

In the Special Report entitled “Potassium Homeostasis in Health and Disease: A Scientific Workshop Cosponsored by the National Kidney Foundation and the American Society of Hypertension” that appeared in the December 2017 issue of *AJKD* (Kovesdy et al, volume 70, issue 6, pages 844-858), there was an error in the financial disclosure statement. The corrected statement is “Financial Disclosure: Dr Kovesdy is a consultant to Relypsa and AstraZeneca. Dr Grams has a grant from the NKF. Dr Palmer reports receipt of consultancy and speaker fees from Relypsa and AstraZeneca. Dr Pitt is a consultant to Relypsa, KBP Pharmaceuticals, Ardelyx, Bayer, Davinci Therapeutics, Merck, Takeda, Boehringer Ingelheim, AstraZeneca, PharMain, Sarfez Pharmaceuticals, scPharmaceuticals, Tricidia, Aurasense, and Forest Laboratories; owns stock options in Relypsa, KBP Pharmaceuticals, Davinci Therapeutics, PharMain, scPharmaceuticals, and Aurasense; and has a patent pending for site-specific delivery of eplerenone to the myocardium. Dr Townsend is a consultant to Relypsa. The remaining authors declare that they have no other relevant financial interests.”